Oncolytics Biotech, Inc.

Innately Adaptive™

Oncolytics Biotech Inc. is developing REOLYSIN®, a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that targets cancer through a unique mechanism of action with two components, selective tumor lysis and activation of the innate and adaptive immune systems, creating an inflamed phenotype to treat a variety of solid tumors and hematological malignancies.

What is Immuno-Oncology?

What is Immuno-Oncology?

Immuno-oncology is a unique medical approach to treating cancer that utilizes the body's own immune system to fight off cancer cells.

How We're Developing REOLYSIN® as an
Immuno-Oncology Agent

Our Focus

We’re committed to developing REOLYSIN® into an effective treatment that can be combined with multiple therapies in order to boost its mechanism of action response.

Program 1: <br>Chemo combinations

Program 1:
Chemo combinations

Taking advantage of stressed tumor cells to initiate cell lysis.

Program 2: <br>Immunomodulator (IMiDs) / targeted therapy combinations

Program 2:
Immunomodulator (IMiDs) / targeted therapy combinations

REOLYSIN® is currently being studied in combination with Celgene's Imnovid® & Revlimid® in a first-of-its-kind immunotherapy trial that aims to modulate the immune system to target myeloma.

Program 3: <br> Immunotherapy combinations

Program 3:
Immunotherapy combinations

An approach, and collaboration opportunity, where REOLYSIN® is combined with immunotherapies (such as with Keytruda in the REO 024 study).

Latest News

Apr 26, 2018

Oncolytics Biotech(R) Announces Details of 2018 Annual General Meeting of Shareholders

Apr 18, 2018

Oncolytics Biotech(R) Demonstrates Positive Data in Two Posters at AACR Annual Meeting 2018

Apr 17, 2018

Oncolytics Biotech(R) Announces Management Change

View All News

Corporate Presentation

Corporate Presentation